Latest news with #UrsulaMatulonis
Medscape
9 hours ago
- Health
- Medscape
ASCO 2025: Key Highlights in Endometrial and Related Cancers
Ursula A. Matulonis, MD, shares highlights from several key studies showcasing promising developments in the treatment of endometrial cancer. A phase 2 trial led by Dr Panagiotis Konstantinopoulos evaluated a combination of letrozole, abemaciclib, and metformin in patients with estrogen receptor (ER)-positive recurrent disease, reporting promising results. In the DUO-E trial, a post hoc circulating tumor (ctDNA) analysis demonstrated that durvalumab-based therapy reduced ctDNA levels, particularly in mismatch repair-deficient tumors, with further reductions observed when olaparib was added during maintenance. Additional studies underscored therapeutic innovation: a phase 2 trial of benmelstobart, an anti-programmed death-ligand 1 (PD-L1) antibody, with or without anlotinib in combination with chemotherapy showed high response rates, and HB0025, a bispecific antibody targeting PD-L1 and VEGF, also achieved encouraging preliminary results in first-line treatment. Beyond endometrial cancer, notable progress was reported across other gynecologic malignancies. In cervical cancer, the phase 3 KEYNOTE-A18 trial confirmed the benefit of pembrolizumab plus concurrent chemoradiotherapy, significantly improving both progression-free and overall survival. In vulvar cancer, a phase 2 trial combining pembrolizumab, cisplatin, and radiation therapy showed encouraging antitumor activity. In another phase 2 trial, the HER2-directed antibody-drug conjugate SHR-A1811 demonstrated promising response rates in ovarian, endometrial, and cervical cancers. In ovarian cancer, the FIRST/ENGOT-OV44 trial did not meet its secondary endpoint with the combination of dostarlimab and niraparib maintenance over niraparib alone. However, the ROSELLA trial showed improved overall survival with the combination of relacorilant (a glucocorticoid receptor antagonist) and nab-paclitaxel in platinum-resistant disease.
Medscape
21-05-2025
- Health
- Medscape
ASCO 2025: A Preview of Advancements in Endometrial Cancer
Ursula A. Matulonis, MD, looks ahead to new developments in gynecologic cancers, especially endometrial cancer, that will be presented at ASCO 2025. She highlights a key phase 2 trial testing the anti-PD-L1 drug benmelstobart plus chemotherapy with or without anlotinib and notes interest in its comparison to lenvatinib-based regimens. Additional noteworthy presentations include data from the DUO-E trial on ctDNA and a triplet-therapy study involving abemaciclib, letrozole, and metformin. Poster sessions will feature emerging treatments like fruquintinib plus sintilimab and the antibody-drug conjugate SHR-A1811. Dr Matulonis also looks forward to phase 3 results in ovarian and cervical cancers, including the KEYNOTE-A18 and ROSELLA studies.
